NOXXON TO HOST KEY OPINION LEADER EVENT ON NOVEL TREATMENT APPROACHES FOR GLIOBLASTOMA ON SEPTEMBER 4th, 2018
Berlin, Germany, August 8, 2018, 6.00 p.m. CEST – NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it will host a Key Opinion Leader (KOL) event focused on novel treatment approaches for glioblastoma.
The event is titled “Novel concepts to tackle the most aggressive form of brain cancer” and will feature world-class thought leaders in neurooncology followed by a question and answer session with NOXXON CEO, Aram Mangasarian. The event will include presentations from:
- Frank A. Giordano, MD, Vice Chair & Associate Professor, Dept. of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg;
- Martin Glas, MD, Professor and Head, Division of Clinical Neurooncology, Dept. of Neurology and Neurooncology Centre at the West German Cancer Centre, University Hospital Essen;
- Ulrich Herrlinger, MD, Professor of Clinical Neurooncology and Head, Division of Clinical Neurooncology, Department of Neurology and Center for Integrated Oncology, University of Bonn;
- Frederik Wenz, MD, CEO and CMO, University Medical Center Mannheim, Professor and Chairman, Dept. of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg.
To RSVP, please send an email with your full name and company details to: BrainCancerEvent@noxxon.com.
NOXXON Pharma N.V.
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 will deliver top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in 2018. The company plans to initiate further studies with NOX-A12 in brain cancer in combination with radiotherapy, for which an orphan drug status has been granted in the US and EU. The company’s second asset, NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in pancreatic cancer patients both as a monotherapy and in combination. Further information can be found at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.